Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells

Transplant Infectious Disease

Volumn 17, Issue 5, 2015, Pages 707-715

  de Ruiter, P E ^a   Boor, P P C ^a   de Jonge, J ^a   Metselaar, H J ^a   Tilanus, H W ^a   Ijzermans, J N ^a   Kwekkeboom, J ^a   van der Laan, L J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Asunaprevir; Daclatasvir; Hepatitis C virus; Interferon alpha; Liver transplantation; Ribavirin

Indexed keywords

ALPHA2A INTERFERON; ASUNAPREVIR; DACLATASVIR; PREDNISOLONE; RIBAVIRIN; TOLL LIKE RECEPTOR 7; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; BMS-790052; IMIDAZOLE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; DRUG ANTAGONISM; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; VIRUS REPLICATION; COMBINATION DRUG THERAPY; DENDRITIC CELL; DRUG EFFECTS; DRUG INTERACTION; HEPATITIS C, CHRONIC; LIVER TRANSPLANTATION; METABOLISM; TUMOR CELL LINE;

ANTIVIRAL AGENTS; BIOMARKERS; CELL LINE, TUMOR; DENDRITIC CELLS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; ISOQUINOLINES; LIVER TRANSPLANTATION; PREDNISOLONE; RIBAVIRIN; SULFONAMIDES;

EID: 84943180949     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12430     Document Type: Article

References (36)

1. Brown RS. Hepatitis C and liver transplantation. Nature 2005; 436 (7053): 973-978.
2. McCaughan GW, Shackel NA, Bertolino P, Bowen DG. Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation 2009; 87 (8): 1105-1111.
3. Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13 (7): 975-983.
4. Terrault NA, Shiffman ML, Lok AS, et al.; A2ALL Study Group. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13 (1): 122-129.
5. Samuel D, Kimmoun E. Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clin Liver Dis 2003; 7 (3): 667-681.
6. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110 (1): 167-177.
7. Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012; 56 (4): 973-983.
8. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5 (4 Suppl 1): S107-S114.
9. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44 (4): 717-722.
10. Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007; 47 (6): 793-798.
11. Llado L, Xiol X, Figueras J, et al.; Thosin Study Group. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006; 44 (4): 710-716.
12. Ramirez CB, Doria C, Frank AM, Armenti ST, Marino IR. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant 2013; 27 (3): 463-471.
13. Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17 (12): 1394-1403.
14. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6 (7): 1586-1599.
15. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 349: g3308.
16. Price JC, Terrault NA. Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl 2015; 21(4): 423-434.
17. Henry SD, Metselaar HJ, Van Dijck J, Tilanus HW, Van Der Laan LJ. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci 2007; 1110: 439-447.
18. Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010; 138 (5): 1875-1884.
19. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010; 1183: 89-103.
20. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010; 234 (1): 142-162.
21. Lau DT, Fish PM, Sinha M, Owen DM, Lemon SM, Gale M Jr. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 2008; 47 (3): 799-809.
22. Takahashi K, Asabe S, Wieland S, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci USA 2010; 107 (16): 7431-7436.
23. Zhang S, Kodys K, Babcock GJ, Szabo G. CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of HCV-infected cells and induction of interferon-alpha. Hepatology 2013; 58 (3): 940-949.
24. Boor PP, Metselaar HJ, Mancham S, Tilanus HW, Kusters JG, Kwekkeboom J. Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant 2006; 6 (10): 2332-2341.
25. Frese M, Schwärzle V, Barth K, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35 (3): 694-703.
26. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11 (7): 791-796.
27. Pan Q, de Ruiter PE, Metselaar HJ, et al. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo. Hepatology 2012; 55 (6): 1673-1683.
28. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995; 57 (3): 318-324.
29. Saeves I, Line PD, Bergan S. The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. Ther Drug Monit 2012; 34 (4): 452-459.
30. Lepelletier Y, Zollinger R, Ghirelli C, et al. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood 2010; 116 (18): 3389-3397.
31. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465 (7300): 937-941.
32. Ferenci P, Kozbial K, Mandorfer M, Hofer H. HCV targeting of patients with cirrhosis. J Hepatol 2015. 63: 1015-1022.
33. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61 (5): 1485-1494.
34. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015; 21 (6): 823-830.
35. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371 (25): 2375-2382.
36. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148 (1): 108-117.